The rapid increase in antibiotic-resistant bacteria has emphasized the urgent need to
identify new treatments for bacterial infections. One attractive approach, reducing the need …

Therapeutic drug development is a long, expensive, and complex process that usually takes
12–15 years. In the early phases of drug discovery, in particular, there is a growing need for …

Paeoniflorin is one of the important components in Paeoniaceae plants. In this study, we
used Caenorhabditis elegans as a model host and Pseudomonas aeruginosa as a bacterial …

Pseudomonas aeruginosa, a re-emerging, opportunistic human pathogen, encodes a
variety of virulence determinants. Pyoverdine, a siderophore produced by this bacterium, is …

Pseudmonas aeruginosa is a Gram-negative bacterium known to be ubiquitous and
recognized as one of the leading causes of infections such as respiratory, urinary tract …

The development of therapies that modulate or prevent pathogen virulence may be a key
strategy for circumventing antimicrobial resistance. Toward that end, we examined the …

Paeoniflorin is the major active compound of total glycoside of paeony in Paeonia lactiflora
Pall. Although several aspects of beneficial effects of paeoniflorin have been described …

Pseudomonas aeruginosa is a clinically important pathogen that causes a variety of
infections, including urinary, respiratory, and other soft-tissue infections, particularly in …

Biofilms create an impermeable barrier against antimicrobial treatment and immune cell
access, severely complicating treatment and clearance of nosocomial Pseudomonas …

The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) infections
is one of the most crucial challenges currently faced by the scientific community …